Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

(2009) W. K. Nevala et al.   CLINICAL CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

(2009) Marianna Sabatino et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis

(2009) Nikhil Yawalkar et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells

(2009) Sayuri Yamazaki et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

(2008) H. van Cruijsen et al.   CLINICAL CANCER RESEARCH

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine

(2008) M. Gigante et al.   MOLECULAR IMMUNOLOGY